Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

The interactive effects of ketamine and magnesium upon depressive-like pathology.

Razmjou S, Litteljohn D, Rudyk C, Syed S, Clarke M, Pentz R, Dwyer Z, Hayley S.

Neuropsychiatr Dis Treat. 2016 Sep 8;12:2049-56. doi: 10.2147/NDT.S111131. eCollection 2016.

2.

Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061.

Latkin CA, Van Tieu H, Fields S, Hanscom BS, Connor M, Hanscom B, Hussen SA, Scott HM, Mimiaga MJ, Wilton L, Magnus M, Chen I, Koblin BA.

AIDS Behav. 2017 Apr;21(4):1163-1170. doi: 10.1007/s10461-016-1493-8.

PMID:
27480454
3.

Major depressive disorder and suicidal behavior among urban dwelling Ethiopian adult outpatients at a general hospital.

Whittier AB, Gelaye B, Deyessa N, Bahretibeb Y, Kelkile TS, Berhane Y, Williams MA.

J Affect Disord. 2016 Jun;197:58-65. doi: 10.1016/j.jad.2016.02.052. Epub 2016 Feb 27.

PMID:
26971124
4.

A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression.

Eisendrath SJ, Gillung E, Delucchi KL, Segal ZV, Nelson JC, McInnes LA, Mathalon DH, Feldman MD.

Psychother Psychosom. 2016;85(2):99-110. doi: 10.1159/000442260. Epub 2016 Jan 26.

5.

Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS).

Fonagy P, Rost F, Carlyle JA, McPherson S, Thomas R, Pasco Fearon RM, Goldberg D, Taylor D.

World Psychiatry. 2015 Oct;14(3):312-21. doi: 10.1002/wps.20267.

6.

Causes of Death in Adults with Mitochondrial Disease.

Barends M, Verschuren L, Morava E, Nesbitt V, Turnbull D, McFarland R.

JIMD Rep. 2016;26:103-13. doi: 10.1007/8904_2015_449. Epub 2015 Sep 10.

7.

A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study.

Wu R, Zhu D, Xia Y, Wang H, Tao W, Xue W, Xia B, Ren L, Zhou X, Li G, Chen G.

Neuropsychiatr Dis Treat. 2015 Aug 6;11:2013-21. doi: 10.2147/NDT.S86585. eCollection 2015.

8.

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.

Singh AB.

Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):150-6. doi: 10.9758/cpn.2015.13.2.150.

9.

Decreased Resting-State Connectivity between Neurocognitive Networks in Treatment Resistant Depression.

de Kwaasteniet BP, Rive MM, Ruhé HG, Schene AH, Veltman DJ, Fellinger L, van Wingen GA, Denys D.

Front Psychiatry. 2015 Mar 2;6:28. doi: 10.3389/fpsyt.2015.00028. eCollection 2015.

10.

A potential role for the acid-sensing T cell death associated gene-8 (TDAG8) receptor in depression-like behavior.

Vollmer LL, Schmeltzer SN, Ahlbrand R, Sah R.

Physiol Behav. 2015 Oct 15;150:78-82. doi: 10.1016/j.physbeh.2015.03.012. Epub 2015 Mar 11.

11.

Elevated level of DNA damage and impaired repair of oxidative DNA damage in patients with recurrent depressive disorder.

Czarny P, Kwiatkowski D, Kacperska D, Kawczyńska D, Talarowska M, Orzechowska A, Bielecka-Kowalska A, Szemraj J, Gałecki P, Śliwiński T.

Med Sci Monit. 2015 Feb 6;21:412-8. doi: 10.12659/MSM.892317.

12.

Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial.

Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A.

World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.

13.

Epigenetic effect of chronic stress on dopamine signaling and depression.

Moriam S, Sobhani ME.

Genet Epigenet. 2013 Feb 10;5:11-6. doi: 10.4137/GEG.S11016. eCollection 2013. Review.

14.

Striatal dopamine D2/3 receptor availability in treatment resistant depression.

de Kwaasteniet BP, Pinto C, Ruhé HG, van Wingen GA, Booij J, Denys D.

PLoS One. 2014 Nov 20;9(11):e113612. doi: 10.1371/journal.pone.0113612. eCollection 2014. Erratum in: PLoS One. 2015;10(8):e0135764. Ruhé, Eric H G [corrected to Ruhé, Henricus G].

15.

Association of subsyndromal and depressive symptoms with inflammatory markers among different ethnic groups: the multi-ethnic study of atherosclerosis (MESA).

Camacho Á, Larsen B, McClelland RL, Morgan C, Criqui MH, Cushman M, Allison MA.

J Affect Disord. 2014 Aug;164:165-70. doi: 10.1016/j.jad.2014.04.018. Epub 2014 Apr 19.

16.

Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.

Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME.

Neuropsychopharmacology. 2014 Oct;39(11):2549-59. doi: 10.1038/npp.2014.101. Epub 2014 May 7.

17.

Disturbance of the glutamatergic system in mood disorders.

Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, Lyoo IK.

Exp Neurobiol. 2014 Mar;23(1):28-35. doi: 10.5607/en.2014.23.1.28. Epub 2014 Mar 27. Review.

18.

Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol.

Eisendrath SJ, Gillung EP, Delucchi KL, Chartier M, Mathalon DH, Sullivan JC, Segal ZV, Feldman MD.

BMC Complement Altern Med. 2014 Mar 11;14:95. doi: 10.1186/1472-6882-14-95.

19.

Depression, stress, and anhedonia: toward a synthesis and integrated model.

Pizzagalli DA.

Annu Rev Clin Psychol. 2014;10:393-423. doi: 10.1146/annurev-clinpsy-050212-185606. Review.

20.

The inflammasome: pathways linking psychological stress, depression, and systemic illnesses.

Iwata M, Ota KT, Duman RS.

Brain Behav Immun. 2013 Jul;31:105-14. doi: 10.1016/j.bbi.2012.12.008. Epub 2012 Dec 20. Review.

Supplemental Content

Support Center